Meiragtx Holdings (MGTX)
NASDAQ:MGTX
Want to see MGTX full AI Analyst Report?
MGTX Stock Chart & Stats
$10.12
-$0.03(-0.47%)
At close: 4:00 PM EST
$10.12
-$0.03(-0.47%)
Day’s Range― - ―
52-Week Range$4.82 - $11.85
Previous CloseN/A
Volume124.17K
Average Volume (3M)942.89K
Market Cap
$887.20M
Enterprise Value$903.19M
Total Cash (Recent Filing)$71.54M
Total Debt (Recent Filing)$87.53M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 06, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding92,609,510
10 Day Avg. Volume802,941
30 Day Avg. Volume942,889
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue11.32
Enterprise Value/Gross Profit12.36
Enterprise Value/Ebitda-9.70
Forecast
1Y Price Target
$24.00Price Target Upside137.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.79
Revenue Forecast (FY)$50.37M
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceMulti-year phase 1 dose-escalation and follow-up data strengthen the gene therapy's efficacy and safety profile for radiation-induced dry mouth, increasing confidence in its potential benefit in later trials.
Funding And PartnershipsCash inflows and collaboration payments extend the development runway and reduce near-term financing risk, supporting continued program advancement and value realization through partnerships.
Ophthalmology Commercial PotentialPositive feedback from patients and physicians and completed technology transfer in the late-stage ophthalmology program enhance commercial readiness and support potential partner or milestone value.
Bears Say
Regulatory Timing UncertaintyUnclear scheduling of regulatory filings and pivotal trials creates uncertainty around when major value inflection points will occur, elevating investor visibility and execution risk.
Meiragtx Holdings News
MGTX FAQ
What was Meiragtx Holdings’s price range in the past 12 months?
Meiragtx Holdings lowest stock price was $4.82 and its highest was $11.85 in the past 12 months.
What is Meiragtx Holdings’s market cap?
Meiragtx Holdings’s market cap is $887.20M.
When is Meiragtx Holdings’s upcoming earnings report date?
Meiragtx Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 77 days.
How were Meiragtx Holdings’s earnings last quarter?
Meiragtx Holdings released its earnings results on May 14, 2026. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.606 by $0.036.
Is Meiragtx Holdings overvalued?
According to Wall Street analysts Meiragtx Holdings’s price is currently Undervalued.
Does Meiragtx Holdings pay dividends?
Meiragtx Holdings does not currently pay dividends.
What is Meiragtx Holdings’s EPS estimate?
Meiragtx Holdings’s EPS estimate is -0.33.
How many shares outstanding does Meiragtx Holdings have?
Meiragtx Holdings has 92,609,510 shares outstanding.
What happened to Meiragtx Holdings’s price movement after its last earnings report?
Meiragtx Holdings reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.606. Following the earnings report the stock price went down -0.201%.
Which hedge fund is a major shareholder of Meiragtx Holdings?
Currently, no hedge funds are holding shares in MGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meiragtx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (137.15% Upside)
$24.00 (137.15% Upside)
Blogger Sentiment
Bullish
MGTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 17.3%
Last 30 Days ▲ 17.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.18%
12-Months-Change
Fundamentals
Return on Equity
474.91%
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Meiragtx Holdings
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
MGTX Stock 12 Month Forecast
Average Price Target
$24.00
▲(137.15% Upside)
Technical Analysis
Ownership Overview
15.57% Insiders
1.97% Mutual Funds
57.31% Other Institutional Investors
22.01% Public Companies and
Individual Investors